| dc.contributor.author | Hardiman, Orla | |
| dc.date.accessioned | 2019-09-03T10:48:24Z | |
| dc.date.available | 2019-09-03T10:48:24Z | |
| dc.date.issued | 2017 | |
| dc.date.submitted | 2017 | en |
| dc.identifier.citation | Peschansky, V., Bedlack, R., Quinn, C., (...), Weber, C., Denson, K.H., ALSUntangled 38: L-serine, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 148-151 | en |
| dc.identifier.other | Y | |
| dc.description | PUBLISHED | en |
| dc.description.abstract | Serine is a ‘‘non-essential’’ amino acid which humans can synthesise (2). Serine exists in 2 forms: L-serine and its mirror image D-serine. L-serine is used in making proteins, while D-serine has other roles including acting as a neuromodulator. Both forms of serine can cross the blood brain barrier and enter the central nervous system | en |
| dc.format.extent | 148-151 | en |
| dc.language.iso | en | en |
| dc.publisher | Informa Healthcare | en |
| dc.relation.ispartofseries | Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration; | |
| dc.relation.ispartofseries | 18; | |
| dc.relation.ispartofseries | 1-2; | |
| dc.rights | Y | en |
| dc.subject | ALSUntangled | en |
| dc.subject | Alternative therapies | en |
| dc.subject | L-serine | en |
| dc.subject | Amyotrophic lateral sclerosis (ALS) | en |
| dc.title | ALSUntangled 38: L-serine | en |
| dc.type | Journal Article | en |
| dc.type.supercollection | scholarly_publications | en |
| dc.type.supercollection | refereed_publications | en |
| dc.identifier.peoplefinderurl | http://people.tcd.ie/hardimao | |
| dc.identifier.rssinternalid | 150341 | |
| dc.identifier.doi | http://dx.doi.org/10.1080/21678421.2016.1250353 | |
| dc.rights.ecaccessrights | openAccess | |
| dc.identifier.orcid_id | 0000-0003-2610-1291 | |
| dc.identifier.uri | https://www.tandfonline.com/doi/full/10.1080/21678421.2016.1250353 | |
| dc.identifier.uri | http://hdl.handle.net/2262/89410 | |
